{"product_id":"slgl-vrio-analysis","title":"Sol-Gel Technologies Ltd. (SLGL): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly fuels Sol-Gel Technologies Ltd. (SLGL)'s success in the market? This VRIO analysis strips away the noise to reveal the hard truth: are their core assets genuinely Valuable, Rare, Inimitable, and Organized for maximum advantage? Dive in now to see the distilled summary of their competitive position and discover the secrets to their potential for sustained profitability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e1. Proprietary Microencapsulation Delivery System\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the engine room of Sol-Gel Technologies Ltd., the silica core-shell microencapsulation platform. This isn't just some lab trick; it’s the fundamental science that lets them combine sensitive actives like tretinoin and benzoyl peroxide in TWYNEO or control the release of benzoyl peroxide in EPSOLAY. That ability to improve efficacy or dial down side effects is what gives their products a real edge in dermatology.\u003c\/p\u003e\n\u003cp\u003eThe value here is clear because it directly translates to commercial success and pipeline potential. Think about it: the U.S. rights for EPSOLAY and TWYNEO alone fetched $16 million in 2025 from Mayne Pharma. Plus, this same tech is key to their lead pipeline asset, SGT-610, which analysts see hitting peak annual revenue potentially exceeding $300 million if approved for Gorlin syndrome. That’s a tangible measure of value.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the commitment: R\u0026amp;D expenses in Q3 2025 hit $5.7 million, with $0.8 million of that specifically tied to SGT-610 manufacturing development. They are defintely putting capital behind this core competency.\u003c\/p\u003e\n\u003cp\u003eThe rarity comes from the specific know-how in applying this silica-based encapsulation to complex dermatological formulations. It’s not just a single patent; it’s the accumulated process control. Imitability is tough because it’s embedded in years of R\u0026amp;D, not just a document you can copy. Organizationally, it’s strong because it’s the central pillar supporting their entire strategy, from their approved products to their most advanced rare disease candidate, SGT-610.\u003c\/p\u003e\n\u003cp\u003eThis platform is what secures a sustained competitive advantage, provided they keep pushing the pipeline forward. If SGT-610 delivers on its potential - top-line results are due in Q4 2026 - this technology becomes even more entrenched as a durable asset.\u003c\/p\u003e\n\u003cp\u003eHere is a quick breakdown of the VRIO assessment for this core technology:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment Summary\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (2025 Fiscal Year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eEnables superior product profiles and high-potential pipeline assets.\u003c\/td\u003e\n\u003ctd\u003eU.S. rights for EPSOLAY and TWYNEO sold for $16 million total consideration in 2025. SGT-610 targets peak revenue over $300 million annually.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eSpecific application and formulation expertise in silica-based encapsulation is unique in dermatology.\u003c\/td\u003e\n\u003ctd\u003eThe technology underpins two FDA-approved products and a lead candidate in Phase 3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh. Know-how is embedded in years of R\u0026amp;D and process control, not easily replicated.\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D expenses in Q3 2025 were $5.7 million, with significant investment in SGT-610 manufacturing development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong. It underpins the entire commercial and R\u0026amp;D focus, evidenced by strategic capital allocation.\u003c\/td\u003e\n\u003ctd\u003eThe company focused resources on SGT-610 development after the $16 million U.S. product rights sale.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained. The platform is a durable asset that creates barriers to entry.\u003c\/td\u003e\n\u003ctd\u003eThe technology is the basis for their entire differentiated product portfolio.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eYou need to make sure the organization capitalizes on the SGT-610 data when it lands. If the Phase 3 trial is positive, the focus must immediately shift to scaling manufacturing capacity beyond the $0.8 million increase in development spend seen in Q3 2025.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e2. FDA-Approved Commercial Products (TWYNEO and EPSOLAY)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe commercial products TWYNEO and EPSOLAY validate the proprietary silica-based microencapsulation technology platform. EPSOLAY is an FDA-approved topical cream containing 5% encapsulated benzoyl peroxide (BPO) for the treatment of inflammatory lesions of rosacea in adults. TWYNEO is an FDA-approved fixed-dose combination cream for acne vulgaris, containing 3% encapsulated benzoyl peroxide and 0.1% encapsulated tretinoin.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides immediate, albeit shared, revenue streams and market proof for the core technology.\u003c\/p\u003e\n\u003cp\u003eThe U.S. rights for both products were sold to a subsidiary of Mayne Pharma Group Limited for a total of $16 million in April 2025. This transaction is expected to extend the Company's cash runway into Q1 2027. Prior to this, the initial agreement with Galderma entitled Sol-Gel to up to $15 million in upfront\/approval payments, tiered double-digit royalties from mid-teen to high-teen percentages of net sales, and up to $9 million in sales milestone payments. Royalty revenue recognized for the six-month periods ended June 30, 2024, and June 30, 2023, was $723 thousand and $466 thousand, respectively. Total revenue for Q3 2024 was $5.4 million, primarily licensing revenue. For the full year 2023, total revenue was $1.6 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies have approved drugs, but few have two approved products based on a novel delivery system.\u003c\/p\u003e\n\u003cp\u003eThe technology platform has resulted in two distinct FDA-approved products, EPSOLAY and TWYNEO.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low for the products themselves (patents expire), but moderate for the specific combination\/formulation.\u003c\/p\u003e\n\u003cp\u003eBoth products utilize Sol-Gel's patented silica-based microencapsulation technology to enhance tolerability and efficacy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. They successfully executed the sale of U.S. rights for $16 million to streamline focus and extend runway into Q1 2027.\u003c\/p\u003e\n\u003cp\u003eThe U.S. rights sale to Mayne Pharma involved $10 million in Q2 2025 and $6 million in Q4 2025. This agreement followed the mutual termination of the exclusive five-year license agreement with Galderma in the U.S. for both products. The company is also establishing a commercial network outside the U.S. through licensing agreements.\u003c\/p\u003e\n\u003cp\u003eThe international licensing efforts include an agreement signed in August 2025 with Viatris for Australia and New Zealand, in addition to seven agreements signed during 2024 covering most European countries, South Africa, and South Korea. These international transactions are anticipated to provide upfront and regulatory milestone payments of up to $3.7 million.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eU.S. Rights Sale (Mayne Pharma)\u003c\/th\u003e\n\u003cth\u003eInternational Licensing (Ex-U.S.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Upfront\/Sale Consideration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$3.7 million\u003c\/strong\u003e in upfront\/milestone payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayment Schedule\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10 million\u003c\/strong\u003e (Q2 2025), \u003cstrong\u003e$6 million\u003c\/strong\u003e (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003ePayments from existing agreements signed in 2024 and anticipated future agreements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnticipated Annual Royalty Potential (Long-Term)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Sale of rights)\u003c\/td\u003e\n\u003ctd\u003ePotential to grow gradually to approximately \u003cstrong\u003e$10 million\u003c\/strong\u003e by \u003cstrong\u003e2031\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The value is being monetized now via licensing\/sale, shifting the advantage to the pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe monetization of U.S. rights for $16 million allows Sol-Gel to focus resources on its lead drug candidate, SGT-610.\u003c\/li\u003e\n\u003cli\u003eThe global potential of TWYNEO and EPSOLAY outside the U.S. is forecasted by management to potentially exceed the value of the U.S. business alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e3. SGT-610: Late-Stage Orphan Drug Candidate\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSGT-610, a topical patidegib gel, is the company's lead asset targeting Gorlin syndrome.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e High potential for first-in-class treatment in a rare disease, commanding premium pricing and market exclusivity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargeting potential peak revenue exceeding \u003cstrong\u003e$300 million annually\u003c\/strong\u003e if approved for Gorlin syndrome.\u003c\/li\u003e\n\u003cli\u003ePursuing high-frequency BCC indication, which could \u003cstrong\u003eat least double\u003c\/strong\u003e the drug's commercial potential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. A Phase 3 topical hedgehog inhibitor for this indication is rare.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 3 clinical trial enrollment for Gorlin syndrome has been \u003cstrong\u003ecompleted\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTop-line results are anticipated in \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3 study involves approximately \u003cstrong\u003e140 subjects\u003c\/strong\u003e at about \u003cstrong\u003e40\u003c\/strong\u003e experienced clinical centers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Regulatory exclusivity (Orphan Drug) combined with clinical success creates a high barrier.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSGT-610 holds \u003cstrong\u003eOrphan Drug designation\u003c\/strong\u003e status in the \u003cstrong\u003eU.S. and E.U.\u003c\/strong\u003e and \u003cstrong\u003eBreakthrough Therapy designation\u003c\/strong\u003e status in the \u003cstrong\u003eU.S.\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe upfront payment for the acquisition of patidegib was \u003cstrong\u003e$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential total commercial milestones related to SGT-610 are up to \u003cstrong\u003e$64.0 million\u003c\/strong\u003e plus single-digit royalties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. They are actively managing manufacturing development expenses to support future commercialization.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric (SGT-610 Related)\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease in R\u0026amp;D Expenses (Clinical Trial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease in R\u0026amp;D Expenses (Manufacturing Development)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease in R\u0026amp;D Expenses (Manufacturing Development)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q2 2025 updates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained (if successful). The combination of clinical data and regulatory status is powerful.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIf approved, SGT-610 is expected to be the \u003cstrong\u003efirst approved product\u003c\/strong\u003e for the prevention of new BCC lesions in Gorlin syndrome patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e4. Focus on Rare\/Unmet Medical Needs (Pipeline Strategy)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is pivoting hard toward rare dermatological diseases with SGT-610 and SGT-210.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for premium pricing, faster regulatory pathways (Orphan Drug), and less direct competition from Big Pharma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs target rare diseases, but few have two late\/mid-stage assets in this specific niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can pivot, but they lack the existing clinical data and institutional knowledge here.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. Management is clearly aligning R\u0026amp;D spend with this focus, supported by transactions extending cash runway.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a good strategy, but others can adopt it if they have the science.\u003c\/p\u003e\n\u003cp\u003ePipeline focus on rare diseases:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSGT-610 (Patidegib gel, 2%) for Gorlin syndrome: Phase 3 enrollment completed; top-line results expected in the \u003cstrong\u003efourth quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSGT-210 (Topical erlotinib) for Darier disease: Proof-of-concept Phase 1b Stage 1 results anticipated in \u003cstrong\u003eDecember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial and Market Potential Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSGT-610 (Gorlin Syndrome)\u003c\/td\u003e\n\u003ctd\u003eSGT-210 (Darier Disease)\u003c\/td\u003e\n\u003ctd\u003eCorporate Financial Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Market Potential (Peak Revenue)\u003c\/td\u003e\n\u003ctd\u003eExceeds \u003cstrong\u003e$300 million\u003c\/strong\u003e annually\u003c\/td\u003e\n\u003ctd\u003eEstimated between \u003cstrong\u003e$200 to $300 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCash runway extended into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Stage \/ Key Milestone\u003c\/td\u003e\n\u003ctd\u003ePhase 3 Completion: \u003cstrong\u003eQ4 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eProof-of-Concept Stage 1 Results: \u003cstrong\u003eDecember 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMayne Pharma U.S. Rights Deal: \u003cstrong\u003e$16 million\u003c\/strong\u003e total consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment Context\u003c\/td\u003e\n\u003ctd\u003eIncreased clinical trial expenses for SGT-610 noted in Q3 2024\u003c\/td\u003e\n\u003ctd\u003eIncreased clinical expenses for SGT-210 noted in Q3 2024\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (9 months ended Sept 30, 2024): \u003cstrong\u003e$12,606 thousand\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional Strategic Financial Alignment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSGT-610 potential commercial value could at least double if pursued for high-frequency BCC indication.\u003c\/li\u003e\n\u003cli\u003eSGT-210 is currently used in compassionate treatment for Olmsted disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e5. Global Licensing and Partnership Network\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe company has successfully monetized its IP through multiple agreements, including the recent one with Viatris and the earlier one with Beimei for China\/HK\/Macau\/Taiwan. These deals bring in non-dilutive capital - like the $16 million from Mayne Pharma - and ensure global reach without Sol-Gel needing to build out massive international sales forces. It’s smart capital deployment.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eTerritory\/Product Focus\u003c\/td\u003e\n\u003ctd\u003eUpfront\/Milestone Consideration (Max)\u003c\/td\u003e\n\u003ctd\u003eRoyalty\/Additional Potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMayne Pharma\u003c\/td\u003e\n\u003ctd\u003eU.S. Rights (EPSOLAY\/TWYNEO)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$16 million\u003c\/strong\u003e (Paid in Q2 2025: \u003cstrong\u003e$10 million\u003c\/strong\u003e; Q4 2025: \u003cstrong\u003e$6 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Product Purchase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeimei Pharma\u003c\/td\u003e\n\u003ctd\u003eChina\/HK\/Macau\/Taiwan\/Israel (TWYNEO)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003eUS$5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSearchlight Pharma\u003c\/td\u003e\n\u003ctd\u003eCanada (EPSOLAY\/TWYNEO)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$11 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLow double-digits to high-teens % of net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalderma (Previous)\u003c\/td\u003e\n\u003ctd\u003eU.S. (EPSOLAY\/TWYNEO)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$15 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTiered royalties from mid- to high-teen % of net sales, plus up to \u003cstrong\u003e$9 million\u003c\/strong\u003e in sales milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe Q2 2025 total revenue was \u003cstrong\u003e$17.2 million\u003c\/strong\u003e, which primarily consisted of \u003cstrong\u003e$0.5 million\u003c\/strong\u003e in royalty revenue from Galderma and \u003cstrong\u003e$16 million\u003c\/strong\u003e from the sale of IP under the agreement with Mayne Pharma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e De-risks commercialization, provides upfront payments, and secures future royalty streams (potentially up to \u003cstrong\u003e$10 million\u003c\/strong\u003e annually by \u003cstrong\u003e2031\u003c\/strong\u003e for TWYNEO\/EPSOLAY).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many specialty pharma firms partner, but the breadth across different territories is a plus.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. These are specific, executed contracts that competitors can’t easily replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The ability to structure and close these complex deals shows capable business development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A proven track record of successful deal-making builds credibility for future negotiations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAgreements signed in 2024 for Europe and South Africa (six agreements) are expected to provide upfront and regulatory milestone payments totaling up to \u003cstrong\u003elow 7-digit USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Mayne Pharma deal is expected to extend the Company's cash runway into the first quarter of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Beimei agreement for TWYNEO in Greater China and Israel is for a total consideration of up to \u003cstrong\u003eUS$15 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e6. Financial Runway Extension to Q1 2027\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eAs of September 30, 2025, the company had \u003cstrong\u003e$20.9 million\u003c\/strong\u003e in cash and securities. Crucially, the strategic transactions have extended the cash runway into the first quarter of 2027. This stability is vital; it means they can fund the final push for SGT-610 results without immediate pressure to raise equity at unfavorable terms. That’s breathing room.\u003c\/p\u003e\n\u003cp\u003eThe extension is supported by specific non-dilutive financing events, notably the agreement for the sale and exclusive license of U.S. rights to EPSOLAY and TWYNEO.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 2025 (Mar 31, 2025)\u003c\/th\u003e\n\u003cth\u003eQ2 2025 (Jun 30, 2025)\u003c\/th\u003e\n\u003cth\u003eProjected Runway End\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash \u0026amp; Securities Balance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Product Sale Consideration Remaining\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.0 million\u003c\/strong\u003e (Expected Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$6.0 million\u003c\/strong\u003e (Expected Q4 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe runway extension to \u003cstrong\u003eQ1 2027\u003c\/strong\u003e is explicitly linked to the expected cash inflow from the product sale agreement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eValue: Provides operational security and allows management to focus on clinical milestones rather than constant fundraising.\u003c\/li\u003e\n\u003cli\u003eRarity: Low. Many clinical-stage companies struggle with this.\u003c\/li\u003e\n\u003cli\u003eImitability: Low. It’s a result of specific past financing and asset sales, not an easily copied resource.\u003c\/li\u003e\n\u003cli\u003eOrganization: Good. Management executed transactions specifically to achieve this runway extension.\u003c\/li\u003e\n\u003cli\u003eCompetitive Advantage: Temporary. It’s a point-in-time advantage that requires constant management to maintain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eKey financial data points underpinning the runway assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe expected top-line results for the SGT-610 Phase 3 trial are targeted for the fourth quarter of 2026.\u003c\/li\u003e\n\u003cli\u003eThe remaining installment from the U.S. product sale is \u003cstrong\u003e$6 million\u003c\/strong\u003e, expected in the fourth quarter of 2025.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses decreased to \u003cstrong\u003e$1.3 million\u003c\/strong\u003e in Q1 2025 from \u003cstrong\u003e$1.8 million\u003c\/strong\u003e in Q1 2024, reflecting cost-saving measures.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q1 2025 was \u003cstrong\u003e$8.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e7. Intellectual Property (IP) Portfolio Strength\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Creates legal barriers to entry and is a direct source of non-dilutive revenue through licensing.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe IP portfolio provides tangible, non-dilutive revenue streams through global out-licensing agreements for approved products like TWYNEO® and EPSOLAY®.\u003c\/p\u003e\n\u003cp\u003eThe company reported total revenue of $5.4 million in Q3 2024, primarily consisting of licensing revenue from partners. For the nine months ended September 30, 2024, total revenue reached $11,260 thousand. The potential value is further quantified by projected annual royalty revenue from TWYNEO and EPSOLAY transactions, anticipated to start at approximately $1 million to $2 million in 2026 and potentially reach up to $10 million by 2030. The potential market for the pipeline asset SGT-610 for Gorlin Syndrome is estimated at more than $300 million.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Asset\/Agreement\u003c\/th\u003e\n\u003cth\u003eTerritory\/Partner\u003c\/th\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount\/Range\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTWYNEO IP\u003c\/td\u003e\n\u003ctd\u003eBeimei (China, HK, Macau, Taiwan, Israel)\u003c\/td\u003e\n\u003ctd\u003eUpfront and Milestone Payments\u003c\/td\u003e\n\u003ctd\u003eUS$10 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTWYNEO IP\u003c\/td\u003e\n\u003ctd\u003eBeimei (China, HK, Macau, Taiwan, Israel)\u003c\/td\u003e\n\u003ctd\u003eRoyalty Payments on Net Sales\u003c\/td\u003e\n\u003ctd\u003eUp to US$5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTWYNEO and EPSOLAY Rights\u003c\/td\u003e\n\u003ctd\u003eSearchlight Pharma (Canada)\u003c\/td\u003e\n\u003ctd\u003eUpfront and Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to $11 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTWYNEO and EPSOLAY Rights\u003c\/td\u003e\n\u003ctd\u003eMayne Pharma (U.S.)\u003c\/td\u003e\n\u003ctd\u003eTotal Consideration\u003c\/td\u003e\n\u003ctd\u003e$16 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTWYNEO and EPSOLAY Rights\u003c\/td\u003e\n\u003ctd\u003eSix European Countries \u0026amp; South Africa\u003c\/td\u003e\n\u003ctd\u003eUpfront and Regulatory Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to low 7-digit USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate. Most pharma companies have IP, but the breadth across both commercial and pipeline assets is key.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe portfolio includes IP covering:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eApproved products: TWYNEO® and EPSOLAY®.\u003c\/li\u003e\n\u003cli\u003ePipeline assets: SGT-610 (Orphan Drug candidate) and SGT-210.\u003c\/li\u003e\n\u003cli\u003eThe SGT-610 Phase 3 trial has completed enrollment, with top-line results expected in the fourth quarter of 2026.\u003c\/li\u003e\n\u003cli\u003eThe SGT-210 proof-of-concept study top-line results are expected in the fourth quarter of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Low. Patents are legally protected monopolies for a set time.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe core technology is protected by patents, which grant a legal monopoly for a defined period, making direct imitation of the patented composition or method legally restricted.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Good. They are actively defending and monetizing this IP through global agreements.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMonetization efforts include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSigning seven new license agreements in July 2024 covering most of Europe and South Africa.\u003c\/li\u003e\n\u003cli\u003eExecuting the asset purchase agreement with Beimei in May 2024.\u003c\/li\u003e\n\u003cli\u003eExecuting the product purchase agreement with Mayne Pharma in Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained. Patents provide a legal, time-bound monopoly.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe legal protection afforded by patents on the microencapsulation delivery system and specific drug candidates provides a time-bound, enforceable barrier against competitors in the covered territories.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e8. Experience in Topical Formulation Development\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. has successfully navigated the complex path from concept to FDA approval for two topical products (TWYNEO and EPSOLAY). This deep, practical experience in developing, manufacturing, and securing regulatory approval for topical drug delivery systems is a specialized skill set that is hard to build quickly. It’s the institutional memory of how to make the gel work.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces the technical risk and time required to develop future topical candidates like SGT-610 and SGT-210.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Successfully commercializing two novel topical products is a rare feat in specialty pharma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This is tacit knowledge gained through experience, not easily written down or bought.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. This experience is embedded in their R\u0026amp;D and manufacturing teams.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is organizational capability that takes years to cultivate.\u003c\/p\u003e\n\u003cp\u003eThe tangible evidence of this experience is reflected in the regulatory milestones and the nature of the approved products:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA approval for TWYNEO Cream was received on \u003cstrong\u003eJuly 27, 2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA approval for EPSOLAY Cream was received on \u003cstrong\u003eApril 22, 2022\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTWYNEO is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide.\u003c\/li\u003e\n\u003cli\u003eEPSOLAY is the first FDA-approved single-active benzoyl peroxide prescription drug product (\u003cstrong\u003e5%\u003c\/strong\u003e BPO).\u003c\/li\u003e\n\u003cli\u003eEPSOLAY received Health Canada approval on \u003cstrong\u003eAugust 27, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis formulation expertise directly impacts the potential value of pipeline assets:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePipeline Asset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\/Target\u003c\/th\u003e\n\u003cth\u003eEstimated Market Potential\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-610 (Patidegib gel, \u003cstrong\u003e2%\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003ePrevention of new BCC lesions in Gorlin syndrome\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e3\u003c\/strong\u003e ongoing; Top-line results expected Q4 \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExceeding \u003cstrong\u003e$300 million\u003c\/strong\u003e annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGT-210 (Topical erlotinib)\u003c\/td\u003e\n\u003ctd\u003eDarier disease\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e1b\u003c\/strong\u003e proof-of-concept ongoing\u003c\/td\u003e\n\u003ctd\u003eEstimated between \u003cstrong\u003e$200 to $300 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financial realization from prior topical product development includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUpfront and regulatory milestone payments up to \u003cstrong\u003e$15 million\u003c\/strong\u003e combined for U.S. licensing of TWYNEO and EPSOLAY, plus up to \u003cstrong\u003e$9 million\u003c\/strong\u003e in sales milestones.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e$3.5 million\u003c\/strong\u003e milestone payment received from Galderma for the FDA approval of EPSOLAY.\u003c\/li\u003e\n\u003cli\u003ePotential for tiered royalties ranging from mid-teen to high-teen percentages of net sales from U.S. commercialization.\u003c\/li\u003e\n\u003cli\u003eUp to \u003cstrong\u003e$11 million\u003c\/strong\u003e in potential upfront, regulatory, and sales milestones for the Canadian licensing of TWYNEO and EPSOLAY, in addition to tiered royalties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSol-Gel Technologies Ltd. (SLGL) - VRIO Analysis: \u003cstrong\u003e9. Strategic Financial Discipline (Cost Control)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maximizes the effective use of existing cash reserves, extending the runway to critical data readouts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Cost control is a necessity, not a unique asset, but their execution is notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. It’s a function of management decisions and operational streamlining.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. The results are visible in the financial statements, showing the measures were effective.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a necessary operational discipline, not a source of long-term market power.\u003c\/p\u003e\n\u003cp\u003eThe results of cost-saving measures taken in 2024 are reflected in the Q3 2025 General and Administrative expenses, which dropped to \u003cstrong\u003e$1 million\u003c\/strong\u003e from \u003cstrong\u003e$1.4 million\u003c\/strong\u003e the prior year (Q3 2024). While Research and Development expenses increased to \u003cstrong\u003e$5.7 million\u003c\/strong\u003e in Q3 2025 from \u003cstrong\u003e$4.8 million\u003c\/strong\u003e in Q3 2024 due to pipeline investment, controlling overhead is crucial when cash is finite. This shows management is making tough calls to preserve capital for the pipeline.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (USD)\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe cash position as of September 30, 2025, totaled \u003cstrong\u003e$20.9 million\u003c\/strong\u003e in cash, cash equivalents, and marketable securities, with an expected cash runway into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, incorporating the Q4 2025 expected payment from Mayne Pharma.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, equivalents and marketable securities balance (as of September 30, 2025): \u003cstrong\u003e$20.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected cash requirement funding period: Into \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected payment from Mayne Pharma (Q4 2025): \u003cstrong\u003e$6 million\u003c\/strong\u003e, part of a total \u003cstrong\u003e$16 million\u003c\/strong\u003e consideration for the U.S. rights to EPSOLAY and TWYNEO.\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A expense reduction (Q3 2025 vs Q3 2024): \u003cstrong\u003e$0.4 million\u003c\/strong\u003e decrease.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D expense increase (Q3 2025 vs Q3 2024): \u003cstrong\u003e$0.9 million\u003c\/strong\u003e increase, primarily related to SGT-610 manufacturing and clinical trial expenses.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516252053653,"sku":"slgl-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/slgl-vrio-analysis.png?v=1740216424","url":"https:\/\/dcf-model.com\/products\/slgl-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}